Lawrence G. Lum

GetPhoto.ashx?photo=LGL4F_1298
  • Phone: 434.243.1375

Primary Appointment

Professor, Director of Cellular Therapy, Scientific Director of Bone Marrow Transplant, Medicine- Hematology and Oncology

Education

  • BS, Chemistry, University of Redlands
  • MD, University of California

Research Interests

Cancer immunotherapy

Research Description

Dr. Lumâs primary focus is enhancing the patientâs immune system to make it a better cancer-killing machine. Cancer immunotherapy works by utilizing a patientâs T cells, which are already programmed to destroy abnormal cells. Grown in the laboratory, the T cells are then directed to target cancer cells. Dr. Lumâs method is unique in how he directs the T cells by linking two antibodies that bind to both T cells and tumor cells and form a killing bridge between the two. Development of this targeting platform allows the procedure to be done simply and adapted quickly to different cancers. Infusions of the targeted T cells create a lasting immunity by vaccinating patients against their own tumors.

Personal Statement

Dr. Lumâs primary focus is enhancing the patientâs immune system to make it a better cancer-killing machine. Cancer immunotherapy works by utilizing a patientâs T cells, which are already programmed to destroy abnormal cells. Grown in the laboratory, the T cells are then directed to target cancer cells. Dr. Lumâs method is unique in how he directs the T cells by linking two antibodies that bind to both T cells and tumor cells and form a killing bridge between the two. Development of this targeting platform allows the procedure to be done simply and adapted quickly to different cancers. Infusions of the targeted T cells create a lasting immunity by vaccinating patients against their own tumors.

Selected Publications

Thakur A, Huang M, Lum LG, Bispecific antibody based therapeutics: Strengths and challenges., 2018; Blood reviews. 32(4) 339-347. PMID: 29482895

Al-Kadhimi Z, Gul Z, Abidi M, Lum LG, Deol A, Chen W, Jang H, Ozust C, Langston A, Waller E, Uberti J, Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention., 2017; Bone marrow transplantation. 52(9) 1304-1310. PMID: 28581472

Thakur A, Lum LG, Mittal S, Bispecific Antibody Armed T Cells to Target Cancer Cells., 2017; Methods in molecular biology (Clifton, N.J.). 1722() 117-126. PMID: 29264802

Modi D, Jang H, Kim S, Surapaneni M, Sankar K, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Chandrasekar P, Uberti JP, Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients., 2017; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 25(8) 2593-2601. PMID: 28365897

Parajuli P, Anand R, Mandalaparty C, Suryadevara R, Sriranga PU, Michelhaugh SK, Cazacu S, Finniss S, Thakur A, Lum LG, Schalk D, Brodie C, Mittal S, Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal., 2016; Oncotarget. 7(5) 6121-35. PMID: 26755664 | PMCID: PMC4868744

Lum LG, Thakur A, Kondadasula SV, Al-Kadhimi Z, Deol A, Tomaszewski EN, Yano H, Schalk DL, Ayash L, Zonder JA, Uberti JP, Abidi MH, Ratanatharathorn V, Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity., 2016; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(5) 869-78. PMID: 26827660

Thakur A, Lum LG, In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer., 2016; Oncoimmunology. 5(3) e1055061. PMID: 27141330 | PMCID: PMC4839366

Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, Lum L, Reyes J, Weise A, Wei WZ, Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination., 2015; Cancer immunology research. 3(7) 777-86. PMID: 25711535 | PMCID: PMC4491035

Mallhi K, Lum LG, Schultz KR, Yankelevich M, Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignancies., 2014; Pediatric clinics of North America. 62(1) 257-73. PMID: 25435122